A few days ago, Johnson & Johnson announced the acquisition of Firefly Bio for $1 billion in cash, once again thrusting Degrader-Antibody Conjugates (DACs), a promising therapeutic field, into the spotlight.

DACs, also known as “next-generation ADCs,” have seen increasing deal-making activity in recent years. Even before Johnson & Johnson’s move, giants such as Bristol Myers Squibb (BMS) and Roche had already placed significant bets on the technology, while domestic Chinese companies including BeiGene, Hengrui Medicine, and Yiliao Biologics are also rushing to enter the space.

The continued high level of interest in DAC drugs can be attributed to the fact that DACs represent an entirely novel antibody conjugation technology, combining the targeting specificity of monoclonal antibodies with the degradation capability of targeted protein degraders (PROTACs or molecular glues), thereby offering the dual advantages of both ADCs and PROTACs.

DACs integrate the precise delivery capability of antibodies with the unique mechanism of action of degraders: leveraging the “precision navigation” of antibodies to achieve tissue- and cell-specific targeted delivery, while utilizing the intracellular “catalytic clearance” mechanism of degraders to directly degrade pathogenic target proteins. This approach overcomes the limitations of traditional “undruggable” targets, achieving a leap in therapeutic efficacy — from inhibition to elimination — while also improving safety.

Buy DAC from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.